175 related articles for article (PubMed ID: 27043118)
1. A Prospective Open-Label Trial of Memantine Hydrochloride for the Treatment of Social Deficits in Intellectually Capable Adults With Autism Spectrum Disorder.
Joshi G; Wozniak J; Faraone SV; Fried R; Chan J; Furtak S; Grimsley E; Conroy K; Kilcullen JR; Woodworth KY; Biederman J
J Clin Psychopharmacol; 2016 Jun; 36(3):262-71. PubMed ID: 27043118
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of memantine in children with autism spectrum disorder: Results from three phase 2 multicenter studies.
Hardan AY; Hendren RL; Aman MG; Robb A; Melmed RD; Andersen KA; Luchini R; Rahman R; Ali S; Jia XD; Mallick M; Lateiner JE; Palmer RH; Graham SM
Autism; 2019 Nov; 23(8):2096-2111. PubMed ID: 31027422
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Memantine in Children with Autism: Randomized, Placebo-Controlled Study and Open-Label Extension.
Aman MG; Findling RL; Hardan AY; Hendren RL; Melmed RD; Kehinde-Nelson O; Hsu HA; Trugman JM; Palmer RH; Graham SM; Gage AT; Perhach JL; Katz E
J Child Adolesc Psychopharmacol; 2017 Jun; 27(5):403-412. PubMed ID: 26978327
[TBL] [Abstract][Full Text] [Related]
4. Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD) - study protocol for a randomised controlled trial.
Häge A; Banaschewski T; Buitelaar JK; Dijkhuizen RM; Franke B; Lythgoe DJ; Mechler K; Williams SC; Dittmann RW;
Trials; 2016 Mar; 17(1):141. PubMed ID: 26983548
[TBL] [Abstract][Full Text] [Related]
5. A pilot open label prospective study of memantine monotherapy in adults with ADHD.
Surman CB; Hammerness PG; Petty C; Spencer T; Doyle R; Napolean S; Chu N; Yorks D; Biederman J
World J Biol Psychiatry; 2013 May; 14(4):291-8. PubMed ID: 22436083
[TBL] [Abstract][Full Text] [Related]
6. Neurocognitive Outcomes from Memantine: A Pilot, Double-Blind, Placebo-Controlled Trial in Children with Autism Spectrum Disorder.
Soorya LV; Fogg L; Ocampo E; Printen M; Youngkin S; Halpern D; Kolevzon A; Lee S; Grodberg D; Anagnostou E
J Child Adolesc Psychopharmacol; 2021 Sep; 31(7):475-484. PubMed ID: 34543081
[No Abstract] [Full Text] [Related]
7. A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders.
Owley T; Salt J; Guter S; Grieve A; Walton L; Ayuyao N; Leventhal BL; Cook EH
J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):517-24. PubMed ID: 17069541
[TBL] [Abstract][Full Text] [Related]
8. Memantine efficacy and safety in patients with acute mania associated with bipolar I disorder: a pilot evaluation.
Keck PE; Hsu HA; Papadakis K; Russo J
Clin Neuropharmacol; 2009; 32(4):199-204. PubMed ID: 19620854
[TBL] [Abstract][Full Text] [Related]
9. Memantine in the Treatment of Executive Function Deficits in Adults With ADHD.
Biederman J; Fried R; Tarko L; Surman C; Spencer T; Pope A; Grossman R; McDermott K; Woodworth KY; Faraone SV
J Atten Disord; 2017 Feb; 21(4):343-352. PubMed ID: 24970718
[TBL] [Abstract][Full Text] [Related]
10. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
Durell TM; Adler LA; Williams DW; Deldar A; McGough JJ; Glaser PE; Rubin RL; Pigott TA; Sarkis EH; Fox BK
J Clin Psychopharmacol; 2013 Feb; 33(1):45-54. PubMed ID: 23277268
[TBL] [Abstract][Full Text] [Related]
11. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial.
Feusner JD; Kerwin L; Saxena S; Bystritsky A
Psychopharmacol Bull; 2009; 42(1):81-93. PubMed ID: 19204653
[TBL] [Abstract][Full Text] [Related]
12. Adjunctive memantine in clozapine-treated refractory schizophrenia: an open-label 1-year extension study.
Veerman SR; Schulte PF; Deijen JB; de Haan L
Psychol Med; 2017 Jan; 47(2):363-375. PubMed ID: 27776560
[TBL] [Abstract][Full Text] [Related]
13. The effect of 12-week open-label memantine treatment on cognitive function improvement in patients with alcohol-related dementia.
Cheon Y; Park J; Joe KH; Kim DJ
Int J Neuropsychopharmacol; 2008 Nov; 11(7):971-83. PubMed ID: 18346293
[TBL] [Abstract][Full Text] [Related]
14. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Tariot PN; Farlow MR; Grossberg GT; Graham SM; McDonald S; Gergel I;
JAMA; 2004 Jan; 291(3):317-24. PubMed ID: 14734594
[TBL] [Abstract][Full Text] [Related]
15. Effect of the Glutamate NMDA Receptor Antagonist Memantine as Adjunctive Treatment in Borderline Personality Disorder: An Exploratory, Randomised, Double-Blind, Placebo-Controlled Trial.
Kulkarni J; Thomas N; Hudaib AR; Gavrilidis E; Grigg J; Tan R; Cheng J; Arnold A; Gurvich C
CNS Drugs; 2018 Feb; 32(2):179-187. PubMed ID: 29549516
[TBL] [Abstract][Full Text] [Related]
16. Symptom overlap on the srs-2 adult self-report between adults with asd and adults with high anxiety.
South M; Carr AW; Stephenson KG; Maisel ME; Cox JC
Autism Res; 2017 Jul; 10(7):1215-1220. PubMed ID: 28266790
[TBL] [Abstract][Full Text] [Related]
17. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability.
Chez MG; Burton Q; Dowling T; Chang M; Khanna P; Kramer C
J Child Neurol; 2007 May; 22(5):574-9. PubMed ID: 17690064
[TBL] [Abstract][Full Text] [Related]
18. Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer's disease: results of a 16-week open-label trial.
Schulz JB; Rainer M; Klünemann HH; Kurz A; Wolf S; Sternberg K; Tennigkeit F
J Alzheimers Dis; 2011; 25(3):463-75. PubMed ID: 21471647
[TBL] [Abstract][Full Text] [Related]
19. Memantine shows promise in reducing gambling severity and cognitive inflexibility in pathological gambling: a pilot study.
Grant JE; Chamberlain SR; Odlaug BL; Potenza MN; Kim SW
Psychopharmacology (Berl); 2010 Dec; 212(4):603-12. PubMed ID: 20721537
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoid treatment for autism: a proof-of-concept randomized trial.
Aran A; Harel M; Cassuto H; Polyansky L; Schnapp A; Wattad N; Shmueli D; Golan D; Castellanos FX
Mol Autism; 2021 Feb; 12(1):6. PubMed ID: 33536055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
